Transplant Infectious Disease · 2008 · 30 citations · 12 references
Life SciencesImmunologyNephrologyImmunotherapyKidney TransplantationTransplant ImmunologyImmunosuppression In Kidney TransplantationTransplant ImmunotherapyTransplant Infectious ComplicationsTransplant PharmacologyBiologic Induction AgentsFungal Infections In Transplant RecipientsInduction ImmunotherapyInfection After TransplantationInfections After TransplantationMortality RatesOverall MortalityTransplant-associated Infections
OBJECTIVES: To report our experience with fungal and mycobacterial (tuberculosis) infection following induction with Campath (alemtuzumab). METHODS: We reviewed the database of 477 renal transplant patients induced with alemtuzumab. All those who had a fungal or mycobacterial infection were found, and the details of these complications reviewed. RESULTS: Five patients were found to have fungal (3) or tuberculous (2) infection. The incidence of fungal infection was 0.6% and that of tuberculous infection was 0.4%. Mortality rates for these 2 types of infection were 50% and 100%, respectively. During the same period, there was an overall mortality of 1.7% (n=5). No surviving patient lost graft function. CONCLUSION: Although fungal and mycobacterial infections caused significant mortality, the overall incidence remains low and comparable to that associated with other induction agents.
12
Predictors and Outcomes of Candiduria in Renal Transplant Recipients
Nasia Safdar, Wendolyn Slattery, V. Knasinski et al. · Clinical Infectious Diseases · 2005 · 149 citations
Campath-1H in renal transplantation: The University of Wisconsin experience
Stuart J. Knechtle, Luis A. Fernandez, John D. Pirsch et al. · Surgery · 2004 · 148 citations
Medicine, Nephrology, Surgery +14